Aspirin and Extended-Release Dipyridamole
Aspirin and extended-release dipyridamole is a combination of two antiplatelet medicines (they make blood platelets less likely to clump) used to lower the risk of stroke in people who have already had a stroke or a stroke-like warning episode.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 4 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Aspirin and extended-release dipyridamole, available as a generic, is one of the standard options for preventing another stroke after an ischemic stroke or TIA (a mini-stroke), though it is prescribed less often than clopidogrel or aspirin alone, and it works because dipyridamole raises adenosine and aspirin blocks thromboxane A2, so platelets clump less. Headache is what most people notice, often strong in the first week and usually easing, along with heartburn or stomach upset. Bleeding is the main risk, so report black or bloody stools, vomiting blood or unusual bruising promptly. If you have coronary artery disease, report new chest pain too, because dipyridamole can make it worse.
Clinical pearls
- Take one capsule in the morning and one in the evening, swallowed whole and never chewed, with or without food.
- Unbearable early headaches have a label-backed workaround, a brief bedtime-only capsule plus low-dose morning aspirin, so call your prescriber before quitting.
- Avoid ibuprofen and similar pain relievers on top of this, since they add bleeding risk and can reduce kidney function.
- Before a heart stress test, tell the testing team you take this, because dipyridamole strengthens adenosine and regadenoson.
Patient information guide A plain-language walkthrough of Aspirin and Extended-Release Dipyridamole, written from its FDA label.
What Aspirin and Extended-Release Dipyridamole is used for
▾
Aspirin and extended-release dipyridamole has one supported use across both listed products.
- Reducing the risk of stroke in people who have had a transient ischemia of the brain (TIA) or a completed ischemic stroke due to thrombosis (a clot).
- This applies to both the Aspirin and Extended-Release Dipyridamole capsule and the Aspirin And Extended-release Dipyridamole extended-release capsule.
How Aspirin and Extended-Release Dipyridamole works
▾
This product combines two antiplatelet medicines whose effects add together. Dipyridamole increases adenosine levels around platelets, which makes them less likely to clump. It also affects an enzyme called phosphodiesterase.
Aspirin permanently blocks the platelet enzyme cyclooxygenase. That lowers thromboxane A2, a chemical that drives platelet clumping and blood vessel narrowing.
Aspirin and Extended-Release Dipyridamole dosage
▾
The usual routine is one capsule by mouth twice a day, morning and evening. Swallow it whole and do not chew it. Food does not matter, so you can take it either way.
- If early headaches are intolerable, your prescriber may switch you briefly to one capsule at bedtime and low-dose aspirin in the morning.
- Return to the usual twice-daily routine as soon as possible, usually within a week.
- Do not swap it for separate aspirin and dipyridamole tablets.
Follow your prescriber and the label for exact directions.
Dosing details from the FDA-approved label
From the Aspirin and Extended-Release Dipyridamole prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Recommended dose (general)
- One capsule given orally twice daily, one in the morning and one in the evening
- Swallow capsules whole without chewing
- Can be administered with or without food
- Not interchangeable with the individual components of aspirin and dipyridamole tablets
- Intolerable headaches during initial treatment (alternative regimen)
- Switch to one capsule at bedtime and low-dose aspirin in the morning
- Return to the usual regimen as soon as possible, usually within one week
- No outcome data with this regimen; headaches become less of a problem as treatment continues
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Aspirin and extended-release dipyridamole capsules are not interchangeable with the individual components of aspirin and dipyridamole tablets. The recommended dose of aspirin and extended-release dipyridamole capsules is one capsule given orally twice daily, one in the morning and one in the evening. Swallow capsules whole without chewing. Aspirin and extended-release dipyridamole capsules can be administered with or without food. One capsule twice daily (morning and evening) with or without food. (2) In case of intolerable headaches during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the morning; resume BID dosing within one week. (2.1) Do not chew capsule. (2) Not interchangeable with the individual components of aspirin and dipyridamole tablets. (2) Dispense in this unit-of-use container. (16) 2.1 Alternative Regimen in Case of Intolerable Headaches In the event of intolerable headaches during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the morning. Because there are no outcome data with this regimen and headaches become less of a problem as treatment continues, patients should return to the usual regimen as soon as possible, usually within one week.
2.1 Alternative Regimen in Case of Intolerable Headaches In the event of intolerable headaches during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the morning. Because there are no outcome data with this regimen and headaches become less of a problem as treatment continues, patients should return to the usual regimen as soon as possible, usually within one week.
Read the full Dosage and Administration section on DailyMed →
Aspirin and Extended-Release Dipyridamole side effects
▾
The most common side effects in studies were:
Common side effects
- Headache
- Indigestion or heartburn (dyspepsia)
- Stomach pain
- Nausea
- Diarrhea
- Vomiting
When to get medical help
- Signs of bleeding, such as black or bloody stools, vomiting blood, nosebleeds that are hard to stop, or unusual bruising. Get medical help.
- Ongoing or severe stomach pain, heartburn or vomiting, which can signal an ulcer or stomach bleeding. Call your doctor.
- Severe allergic reaction, such as hives, swelling or wheezing and trouble breathing. Get help right away.
- New or worsening chest pain, especially if you have coronary artery disease. Call your doctor.
- Headaches that are too much to handle early in treatment. Call your prescriber about the alternative plan.
- Ringing in the ears, dizziness, flushing or weakness after taking too much. Seek medical care or call Poison Control.
Headache and stomach upset were also common reasons people stopped the medicine. Get medical help for signs of bleeding, severe stomach pain, allergic reactions, or worsening chest pain.
Aspirin and Extended-Release Dipyridamole warnings and precautions
▾
- Bleeding: the risk is higher, including bleeding in the stomach, intestines and brain. Other blood thinners, antiplatelets, NSAIDs and heavy drinking add to it.
- Stomach problems: avoid it with active peptic ulcer disease. Watch for ulcers and bleeding even if you never had stomach symptoms.
- Pregnancy: aspirin can harm a baby, especially in the third trimester.
- Heart and blood pressure: dipyridamole can trigger or worsen chest pain with coronary artery disease and can worsen low blood pressure.
- Kidney and liver: avoid it in severe kidney or severe liver problems. Liver enzyme rises and liver failure have been reported with dipyridamole.
Aspirin and Extended-Release Dipyridamole interactions
▾
Many medicines can interact with this combination, mostly because of the aspirin.
- Blood thinners, antiplatelets, anagrelide and NSAIDs: higher bleeding risk.
- Adenosine and regadenoson: dipyridamole boosts their heart effects.
- ACE inhibitors, beta blockers and diuretics: aspirin may weaken their effects.
- Cholinesterase inhibitors: dipyridamole may counteract them and worsen myasthenia gravis.
- Methotrexate and acetazolamide: levels may rise to harmful amounts.
- Phenytoin and valproic acid: aspirin changes their blood levels.
- Oral diabetes medicines: low blood sugar may be more likely.
- Probenecid and sulfinpyrazone: aspirin blocks their effect.
- Alcohol: three or more drinks daily raises bleeding risk.
Interactions listed in the FDA-approved label
From the Aspirin and Extended-Release Dipyridamole prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Adenosinergic agents (e.g., adenosine, regadenoson): Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine, and also increases the cardiovascular effects of regadenoson. Adjustment of adenosine dosage may be necessary.
- Angiotensin Converting Enzyme (ACE) Inhibitors: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin.
- Acetazolamide: Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion.
- Anticoagulants and Antiplatelets: Patients taking this combination with anticoagulants, antiplatelets, or any substance impacting coagulation are at increased risk for bleeding; aspirin can displace warfarin from protein binding sites and can increase the anticoagulant activity of heparin.
- Anagrelide: Patients taking aspirin in combination with anagrelide are at an increased risk of bleeding.
- Anticonvulsants (phenytoin, valproic acid): Salicylic acid can displace protein-bound phenytoin and valproic acid, decreasing total phenytoin concentration and increasing serum valproic acid levels.
- Beta Blockers: The hypotensive effects of beta blockers may be diminished by aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention.
- Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, potentially aggravating myasthenia gravis.
- Diuretics: The effectiveness of diuretics in patients with underlying renal or cardiovascular disease may be diminished by aspirin due to inhibition of renal prostaglandins.
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Concurrent use of aspirin with other NSAIDs may increase bleeding or lead to decreased renal function.
Read the label’s full interactions text
7 DRUG INTERACTIONS Co-administration with anticoagulants, antiplatelets, or NSAIDs can increase risk of bleeding. (7.1) Decreased renal function can occur with co-administration with NSAIDs. (7.1) 7.1 Drug Interaction Study Information Obtained From Literature Adenosinergic agents (e.g., adenosine, regadenoson) Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Dipyridamole also increases the cardiovascular effects of regadenoson, an adenosine A 2A -receptor agonist. The potential risk of cardiovascular side effects with intravenous adenosinergic agents may be increased during the testing period when dipyridamole is not held 48 hours prior to stress testing. Angiotensin Converting Enzyme (ACE) Inhibitors Because of the indirect effect of aspirin on the renin-angiotensin conversion pathway, the hyponatremic and hypotensive effects of ACE inhibitors may be diminished by concomitant administration of aspirin. Acetazolamide Concurrent use of aspirin and acetazolamide can lead to high serum concentrations of acetazolamide (and toxicity) due to competition at the renal tubule for secretion. Anticoagulants and Antiplatelets Patients taking aspirin and extended-release dipyridamole in combination with anticoagulants, antiplatelets, or any substance impacting coagulation are at increased risk for bleeding. Aspirin can displace warfarin from protein binding sites, leading to prolongation of both the prothrombin time and the bleeding time. Aspirin can increase the anticoagulant activity of heparin, increasing bleeding risk. Anagrelide Patients taking aspirin in combination with anagrelide are at an increased risk of bleeding. Anticonvulsants Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Aspirin and Extended-Release Dipyridamole
▾
- Do not use if allergic to any ingredient, to NSAIDs, or if you have asthma with rhinitis and nasal polyps.
- Not recommended for children and teenagers, because of Reye syndrome risk with viral infections.
- Avoid in the third trimester of pregnancy. Tell your doctor if you are or may become pregnant.
- Breastfeeding: small amounts pass into milk, so discuss it with your doctor.
- Avoid in severe kidney or severe liver problems.
- Tell your doctor about peptic ulcer disease, coronary artery disease or low blood pressure.
- Older adults did about as well as younger adults, but some may be more sensitive.
Aspirin and Extended-Release Dipyridamole overdose
▾
An overdose is likely to show mostly dipyridamole effects, such as warm feeling, flushing, sweating, restlessness, weakness, dizziness, low blood pressure and fast heartbeat. Too much aspirin can cause ringing in the ears and, in severe cases, fever and fluid loss. For a real or suspected overdose, get medical attention or call Poison Control right away.
What Aspirin and Extended-Release Dipyridamole does in the body
▾
The blood-thinning effect comes from the added antiplatelet actions of dipyridamole and aspirin. How each medicine affects the other's action on platelets has not been studied.
How your body processes Aspirin and Extended-Release Dipyridamole
▾
Dipyridamole levels peak about 2 hours after a dose. Aspirin peaks within about 30 to 60 minutes. A high-fat meal lowers absorption somewhat, but the label says this does not matter clinically. The two medicines do not significantly affect each other's handling in the body.
Dipyridamole is broken down in the liver and leaves mostly through bile into the stool. Aspirin is partly converted to salicylic acid in the liver and gut wall. Dipyridamole levels were about 40% higher in healthy adults over 65.
How to store Aspirin and Extended-Release Dipyridamole
▾
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) . Protect from excessive moisture.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Aspirin and Extended-Release Dipyridamole: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Aspirin and Extended-Release Dipyridamole — the kind of thing our pharmacy team would talk through with you at the counter.
What is this medicine for?
▾
How should I take it?
▾
I get bad headaches since starting. What should I do?
▾
What side effects should I call about?
▾
Can I take other pain relievers or blood thinners with it?
▾
Is it safe in pregnancy?
▾
Is Aspirin and Extended-Release Dipyridamole available over the counter?
▾
When was Aspirin and Extended-Release Dipyridamole first available?
▾
Who makes Aspirin and Extended-Release Dipyridamole?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Aspirin and Extended-Release Dipyridamole on HelloPharmacist
Aspirin and Extended-Release Dipyridamole forms and strengths (how it comes)
Aspirin and Extended-Release Dipyridamole is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Aspirin and Extended-Release Dipyridamole inactive ingredients by manufacturer.
Capsule
How this form is used
- Aspirin and Extended-Release Dipyridamole capsules are used to reduce the risk of stroke after a TIA or ischemic stroke due to thrombosis.
- Aspirin and Extended-Release Dipyridamole capsules are taken by mouth, one in the morning and one in the evening.
- Swallow Aspirin and Extended-Release Dipyridamole capsules whole, without chewing.
- Aspirin and Extended-Release Dipyridamole capsules can be taken with or without food.
- Aspirin and Extended-Release Dipyridamole capsules are not interchangeable with separate aspirin and dipyridamole tablets.
Extended-release capsule
How this form is used
- Aspirin And Extended-release Dipyridamole extended-release capsules are used to reduce the risk of stroke after a TIA or ischemic stroke due to thrombosis.
- Aspirin And Extended-release Dipyridamole extended-release capsules are taken by mouth, one in the morning and one in the evening.
- Swallow Aspirin And Extended-release Dipyridamole capsules whole, without chewing.
- Aspirin And Extended-release Dipyridamole can be taken with or without food.
- Aspirin And Extended-release Dipyridamole is not interchangeable with separate aspirin and dipyridamole tablets.
Aspirin and Extended-Release Dipyridamole on the U.S. market: products, makers and brands
How Aspirin and Extended-Release Dipyridamole appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
4 companies list 4 Aspirin and Extended-Release Dipyridamole product records with the FDA, mostly as capsule, extended-release capsule; the earliest marketing or approval year on record is 2016.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Aspirin and Extended-Release Dipyridamole is used (Medicaid data)
A general measure of how commonly Aspirin and Extended-Release Dipyridamole is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Aspirin and Extended-Release Dipyridamole is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Aspirin and Extended-Release Dipyridamole prescribed? Of the 1,601 medications we measure, Aspirin and Extended-Release Dipyridamole ranks #1,418 by Medicaid prescriptions — more than 11% of them.
Utilization by Aspirin and Extended-Release Dipyridamole product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
Other Aspirin and Extended-Release Dipyridamole products — combination packs and listings not yet matched to a specific clinical product (kept visible so every prescription is accounted for)
Summed across the 2 of 4 listed NDC products with Medicaid activity.
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Aspirin and Extended-Release Dipyridamole, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 2 of 4 listed Aspirin and Extended-Release Dipyridamole NDCs with Medicaid activity.
Compare Aspirin and Extended-Release Dipyridamole products
A representative set of FDA-listed product records for Aspirin and Extended-Release Dipyridamole — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| ASPIRIN 25 mg/1; DIPYRIDAMOLE 200 mg | Oral | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| ASPIRIN 25 mg/1; DIPYRIDAMOLE 200 mg | Oral | AvKARE | ANDA | View NDC → |
| 💊Extended-release capsule | ||||
| ASPIRIN 25 mg/1; DIPYRIDAMOLE 200 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| ASPIRIN 25 mg/1; DIPYRIDAMOLE 200 mg | Oral | Micro Labs Limited | ANDA | View NDC → |
Showing 4 of 4 products — FDA National Drug Code Directory. See every product, package size and price: browse all 4 Aspirin and Extended-Release Dipyridamole NDCs →
Aspirin and Extended-Release Dipyridamole side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Aspirin and Extended-Release Dipyridamole — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Aspirin and Extended-Release Dipyridamole in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Aspirin and Extended-Release Dipyridamole FDA approval history
How Aspirin and Extended-Release Dipyridamole went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Aspirin and Extended-Release Dipyridamole recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Aspirin and Extended-Release Dipyridamole recalls since July 2021.
✅No Aspirin and Extended-Release Dipyridamole recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
Aspirin and Extended-Release Dipyridamole supply and shortage status
Whether Aspirin and Extended-Release Dipyridamole is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Aspirin and Extended-Release Dipyridamole costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Capsule, Extended Release · Oral | 25; 200 mg/1; mg | $0.559 per capsule | NDC details & price history |
| Capsule, Extended Release · Oral | ASPIRIN 25 mg/1; DIPYRIDAMOLE 200 mg | $0.559 per capsule | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Who makes Aspirin and Extended-Release Dipyridamole: manufacturers and labelers
4 companies list Aspirin and Extended-Release Dipyridamole products with the FDA. By number of product records, the largest are Amneal Pharmaceuticals LLC, AvKARE, Bryant Ranch Prepack. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Aspirin and Extended-Release Dipyridamole drug class (RxNorm)
Aspirin and Extended-Release Dipyridamole belongs to the Platelet Aggregation Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Aspirin and Extended-Release Dipyridamole page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. AvKARE is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →